Physician profile
Jon A Sexton
NPI 1699703496
$2,140.52
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,068 · 2020: $846 · 2021: $227.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $932.30 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $382.17 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.27 | 2019-2021 | |
| Abbvie INC. | $83.13 | 2019-2021 | |
| Allergan, INC. | $77.99 | 2019-2020 | |
| Circassia INC. | $57.51 | 2019-2020 | |
| Insmed, INC. | $56.41 | 2019-2020 | |
| Csl Behring | $50.77 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $49.47 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $47.20 | 2019-2021 | |
| Covidien Lp | $37.71 | 2020 | |
| Novartis Pharmaceuticals Corporation | $33.33 | 2019-2020 | |
| Genzyme Corporation | $29.76 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $26.58 | 2019 | |
| Shire North American Group INC | $25.06 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $18.93 | 2019 | |
| Daiichi Sankyo INC. | $18.65 | 2019 | |
| Qol Medical, LLC | $17.20 | 2020 | |
| Advanced Respiratory, INC | $17.01 | 2020 | |
| Merck Sharp & Dohme LLC | $16.88 | 2021 | |
| Esperion Therapeutics, INC. | $13.27 | 2020 | |
| Amneal Pharmaceuticals LLC | $13.09 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.40 | 2020 | |
| Novo Nordisk INC | $11.96 | 2019 | |
| Mallinckrodt Enterprises LLC | $11.88 | 2019 | |
| Intercept Pharmaceuticals, INC. | $11.59 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Sexton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.